

Didier Fradelizi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7812120/publications.pdf>

Version: 2024-02-01

44
papers

2,251
citations

257101

24
h-index

243296

44
g-index

44
all docs

44
docs citations

44
times ranked

2482
citing authors

#	ARTICLE	IF	CITATIONS
1	Identification of Quantitative Trait Loci responsible for embryonic lethality in mice assessed by ultrasonography. <i>International Journal of Developmental Biology</i> , 2009, 53, 623-629.	0.3	20
2	Dramatic efficacy improvement of a DC-based vaccine against AML by CD25 T cell depletion allowing the induction of a long-lasting T cell response. <i>Cancer Immunology, Immunotherapy</i> , 2009, 58, 1669-1677.	2.0	28
3	Delivery of mengovirus-derived RNA replicons into tumoural liver enhances the anti-tumour efficacy of a peripheral peptide-based vaccine. <i>Cancer Immunology, Immunotherapy</i> , 2008, 57, 1161-1171.	2.0	5
4	DC-based vaccine loaded with acid-eluted peptides in acute myeloid leukemia: the importance of choosing the best elution method. <i>Cancer Immunology, Immunotherapy</i> , 2006, 56, 1-12.	2.0	16
5	TLR2: for or against <i>Candida albicans</i> ?. <i>Trends in Microbiology</i> , 2005, 13, 298-299.	3.5	14
6	Autologous peptides eluted from acute myeloid leukemia cells can be used to generate specific antileukemic CD4 helper and CD8 cytotoxic T lymphocyte responses in vitro. <i>Haematologica</i> , 2005, 90, 1050-62.	1.7	12
7	Regression of Established Liver Tumor Induced by Monoepitopic Peptide-Based Immunotherapy. <i>Journal of Immunology</i> , 2004, 173, 4882-4888.	0.4	12
8	Toll-like receptor 2 is dispensable for acquired host immune resistance to <i>Candida albicans</i> in a murine model of disseminated candidiasis. <i>Microbes and Infection</i> , 2004, 6, 542-548.	1.0	52
9	Toll-like receptor-2 is essential in murine defenses against <i>Candida albicans</i> infections. <i>Microbes and Infection</i> , 2004, 6, 1-7.	1.0	194
10	GRP78, a Coreceptor for Coxsackievirus A9, Interacts with Major Histocompatibility Complex Class I Molecules Which Mediate Virus Internalization. <i>Journal of Virology</i> , 2002, 76, 633-643.	1.5	183
11	Auto-protective redox buffering systems in stimulated macrophages. <i>BMC Immunology</i> , 2002, 3, 3.	0.9	50
12	Inflammation and cancer, the mastocytoma P815 tumor model revisited: Triggering of macrophage activation in vivo with pro-tumorigenic consequences. <i>International Journal of Cancer</i> , 2002, 100, 571-579.	2.3	23
13	Major histocompatibility class one molecule associates with glucose regulated protein (GRP) 78 on the cell surface. <i>Human Immunology</i> , 2001, 62, 764-770.	1.2	59
14	Inhibition of Transforming Growth Factor- β Signaling Accelerates Atherosclerosis and Induces an Unstable Plaque Phenotype in Mice. <i>Circulation Research</i> , 2001, 89, 930-934.	2.0	442
15	The type II decoy receptor of IL-1 inhibits murine collagen-induced arthritis. <i>European Journal of Immunology</i> , 2000, 30, 867-875.	1.6	85
16	Stable polarization of peripheral blood T cells towards type 1 or type 2 phenotype after polyclonal activation. <i>European Journal of Immunology</i> , 1998, 28, 532-539.	1.6	15
17	Signaling through the tetraspanin CD82 triggers its association with the cytoskeleton leading to sustained morphological changes and T cell activation. <i>European Journal of Immunology</i> , 1998, 28, 4332-4344.	1.6	54
18	Cytokines: médiateurs de la réponse immunitaire et de l'action inflammatoire. <i>Annales De L'Institut Pasteur / Actualités</i> , 1998, 9, 95-106.	0.1	1

#	ARTICLE	IF	CITATIONS
19	Detection of Membrane Associated Thioredoxin on Human Cell Lines. Biochemical and Biophysical Research Communications, 1997, 230, 602-606.	1.0	31
20	Control of B cell lymphoma recognition via natural killer inhibitory receptors implies a role for human V β 9/V α 2 T cells in tumor immunity. European Journal of Immunology, 1997, 27, 3368-3379.	1.6	115
21	Attenuation of collagen-induced arthritis in mice by treatment with vector cells engineered to secrete interleukin-13. European Journal of Immunology, 1996, 26, 2399-2403.	1.6	163
22	Systemic Antitumor Effects of Electrochemotherapy Combined with Histoincompatible Cells Secreting Interleukin-2. Journal of Immunotherapy, 1995, 17, 30-38.	1.2	92
23	CD82, tetra-span-transmembrane protein, is a regulated transducing molecule on U937 monocytic cell line. Journal of Leukocyte Biology, 1995, 57, 956-963.	1.5	34
24	Experimental gene therapy of cancer using tumor cells engineered to secrete interleukin-13. European Journal of Immunology, 1995, 25, 2340-2348.	1.6	48
25	Further Characterization of CD82/IA4 Antigen (Type III Surface Protein): An Activation/Differentiation Marker of Mononuclear Cells. Cellular Immunology, 1994, 154, 468-483.	1.4	37
26	Genomic cloning of human thioredoxin-encoding gene: mapping of the transcription start point and analysis of the promoter. Gene, 1994, 140, 273-278.	1.0	56
27	Inhibition of tumor growth by histoincompatible cells expressing interleukin-2. International Immunology, 1992, 4, 1429-1436.	1.8	27
28	Target lysis by human lak cells is critically dependent upon target binding properties, but LFA-1, LFA-3 AND ICAM-1 are not the major adhesion ligands on targets. International Journal of Cancer, 1991, 47, 473-479.	2.3	40
29	An improved double fluorescence flow cytometry method for the quantification of killer cell/target cell conjugate formation. Journal of Immunological Methods, 1990, 130, 251-261.	0.6	36
30	Interleukin 2 stimulates tyrosine phosphorylation in T cell membrane fractions. FEBS Journal, 1989, 185, 455-459.	0.2	9
31	Functional interactions of IL2 and TNF in the differentiation of LGL into lak effectors. International Journal of Cancer, 1989, 44, 598-604.	2.3	29
32	An improved electrotransfection method using square shaped electric impulses. Biochemical and Biophysical Research Communications, 1988, 151, 982-990.	1.0	22
33	Lack of reconstitution of nude mice alloreactivity by purified interleukin 2 and induction of non-H-2-specific effector cells by crude supernatants. Cellular Immunology, 1987, 105, 251-261.	1.4	3
34	Anti-Myelin Basic Protein Autoreactive T Lymphocytes in Healthy Subjects and Multiple Sclerosis Patients. Annals of the New York Academy of Sciences, 1986, 475, 404-406.	1.8	11
35	Differentiation factors for human specific B cell response. European Journal of Immunology, 1986, 16, 803-808.	1.6	13
36	Modulation of c-fos and c-myc mRNA levels in normal human lymphocytes by calcium ionophore A23187 and phorbol ester. European Journal of Immunology, 1986, 16, 1217-1221.	1.6	44

#	ARTICLE	IF	CITATIONS
37	Accessory function of human leukemic cell lines: properties of B and B-K562 hybrid cell lines. <i>European Journal of Immunology</i> , 1985, 15, 256-261.	1.6	7
38	T lymphocyte function during experimental Chagas' disease: production of and response to interleukin 2. <i>European Journal of Immunology</i> , 1985, 15, 438-442.	1.6	61
39	Heterogeneous accessory cell requirement for human peripheral blood T lymphocyte activation by PHA into IL-2-responsive colony-forming cells. <i>Cellular Immunology</i> , 1984, 87, 167-176.	1.4	5
40	Improved culture conditions for quantitative evaluation of interleukin 2 production by frozen human lymphocytes. <i>Journal of Immunological Methods</i> , 1983, 64, 61-69.	0.6	7
41	Analysis of stimulating products involved in primary and secondary allogenic proliferation in man. <i>Immunogenetics</i> , 1978, 6, 29-42.	1.2	30
42	Analysis of products involved in primary and secondary allogenic proliferation in man. <i>Immunogenetics</i> , 1978, 6, 43-54.	1.2	20
43	Analysis of products involved in primary and secondary allogenic proliferation in man. <i>Immunogenetics</i> , 1978, 6, 55-68.	1.2	23
44	Secondary response of in vitro-primed human lymphocytes to allogeneic cells. <i>Immunogenetics</i> , 1976, 3, 29-40.	1.2	23